196 related articles for article (PubMed ID: 30536809)
41. Electroneurography in the evaluation of oxaliplatin-induced neuropathy in colorectal cancer patients.
Zygulska AL; Banach M; Krzemieniecki K
Neoplasma; 2016; 63(4):617-22. PubMed ID: 27268926
[TBL] [Abstract][Full Text] [Related]
42. Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population.
Zribi A; Nasr SB; Hamdi S; Ayari J; Fendri S; Balti M; Haddaoui A
Pan Afr Med J; 2020; 35():83. PubMed ID: 32537086
[TBL] [Abstract][Full Text] [Related]
43. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
44. Assessment of Oxaliplatin-induced Chronic Neuropathy and Anticancer Efficacy Through Pharmacokinetic and Toxicodynamic Evaluation of a Rat Model of Colorectal Cancer.
Ito Y; Kobuchi S; Takesada W; Takahashi C
Anticancer Res; 2019 Aug; 39(8):4207-4213. PubMed ID: 31366507
[TBL] [Abstract][Full Text] [Related]
45. Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study.
Uchida M; Kawazoe H; Takatori S; Namba H; Uozumi R; Tanaka A; Kawasaki H; Araki H
Clin Ther; 2018 Jul; 40(7):1214-1222.e1. PubMed ID: 29983264
[TBL] [Abstract][Full Text] [Related]
46. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.
Pulvers JN; Marx G
Asia Pac J Clin Oncol; 2017 Dec; 13(6):345-355. PubMed ID: 28653815
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
[TBL] [Abstract][Full Text] [Related]
48. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
[TBL] [Abstract][Full Text] [Related]
49. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review.
Gebremedhn EG; Shortland PJ; Mahns DA
BMC Cancer; 2018 Apr; 18(1):410. PubMed ID: 29649985
[TBL] [Abstract][Full Text] [Related]
50. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
51. Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities: A Longitudinal Study Among Patients With Colorectal Cancer.
Drott J; Fomichov V; Starkhammar H; Börjeson S; Kjellgren K; Berterö C
Cancer Nurs; 2019; 42(6):E40-E48. PubMed ID: 31658096
[TBL] [Abstract][Full Text] [Related]
52. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial.
Chan K; Lui L; Lam Y; Yu K; Lau K; Lai M; Lau W; Tai L; Mak C; Bian Z; Zhong LL
Acupunct Med; 2023 Oct; 41(5):268-283. PubMed ID: 36325677
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
55. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).
Pachman DR; Qin R; Seisler D; Smith EM; Kaggal S; Novotny P; Ruddy KJ; Lafky JM; Ta LE; Beutler AS; Wagner-Johnston ND; Staff NP; Grothey A; Dougherty PM; Cavaletti G; Loprinzi CL
Support Care Cancer; 2016 Dec; 24(12):5059-5068. PubMed ID: 27534963
[TBL] [Abstract][Full Text] [Related]
56. Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN).
Argyriou AA
Toxics; 2015 May; 3(2):187-197. PubMed ID: 29056657
[TBL] [Abstract][Full Text] [Related]
57. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
58. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
59. Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.
Kandula T; Farrar MA; Krishnan AV; Murray J; Timmins HC; Goldstein D; Lin CS; Kiernan MC; Park SB
Muscle Nerve; 2018 Apr; 57(4):615-621. PubMed ID: 28881477
[TBL] [Abstract][Full Text] [Related]
60. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
